HC Wainwright reissued their buy rating on shares of Inozyme Pharma (NASDAQ:INZY – Free Report) in a report issued on Tuesday,Benzinga reports. They currently have a $16.00 price objective on the stock.
Several other equities research analysts have also issued reports on the stock. Wells Fargo & Company lowered their price target on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Needham & Company LLC dropped their price target on shares of Inozyme Pharma from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday. Raymond James began coverage on shares of Inozyme Pharma in a research note on Thursday, December 12th. They issued an “outperform” rating and a $26.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $7.00 price objective (down previously from $12.00) on shares of Inozyme Pharma in a research note on Monday. Finally, Piper Sandler decreased their target price on Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $16.11.
View Our Latest Research Report on Inozyme Pharma
Inozyme Pharma Stock Performance
Institutional Investors Weigh In On Inozyme Pharma
Hedge funds have recently made changes to their positions in the business. Harvest Investment Services LLC bought a new stake in shares of Inozyme Pharma during the 4th quarter valued at $31,000. Graham Capital Management L.P. purchased a new stake in shares of Inozyme Pharma in the fourth quarter worth about $33,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Inozyme Pharma during the 4th quarter worth approximately $38,000. D. E. Shaw & Co. Inc. purchased a new position in shares of Inozyme Pharma during the fourth quarter worth approximately $49,000. Finally, ProShare Advisors LLC purchased a new position in Inozyme Pharma during the 4th quarter valued at about $49,000. 88.30% of the stock is currently owned by institutional investors.
Inozyme Pharma Company Profile
Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
Featured Stories
- Five stocks we like better than Inozyme Pharma
- Following Congress Stock Trades
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- How to Most Effectively Use the MarketBeat Earnings Screener
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- What Are Dividends? Buy the Best Dividend Stocks
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.